scholarly journals Diarrhea syndrome: new accents of patient curation during COVID-19 pandemic

2021 ◽  
Vol 5 (6) ◽  
pp. 446-452
Author(s):  
O.V. Gaus ◽  
◽  
M.A. Livzan ◽  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Ischemic Colitis ◽  
Clinical Manifestations ◽  
Gastrointestinal Symptoms ◽  
Gastrointestinal Disorder ◽  
Infected People ◽  
Antibiotic Associated Diarrhea ◽  
Irritable Bowel ◽  
Diarrhea Syndrome ◽  
Post Infectious

The digestive tract, like the respiratory organs, is the entrance gate for SARS-CoV-2. At the same time, diarrhea is one of the most common gastrointestinal symptoms among infected people. As the debut of COVID-19 clinical manifestations, diarrhea can be associated both with the direct cytopathic effect of the virus on the intestinal mucosal epithelium and with the gut microbiota modulation. During the period of the expanded clinical picture of COVID-19, diarrhea syndrome is commonly associated with the adverse event of drug therapy, primarily antibiotics, nonsteroidal anti-inflammatory drugs, antiviral agents, antiplatelet agents and anticoagulants, as well as with possible involvement in the pathological process of the liver and pancreas with a violation of their functional activity. Finally, after the infection, the repeated occurrence of diarrhea requires the exclusion of antibiotic-associated diarrhea, including those caused by Clostridium difficile, as well as ischemic colitis and post-infectious irritable bowel syndrome. Besides, despite the pandemic, it should not be forgotten about the possible debut of gastrointestinal disorder or an exacerbation of already existing chronic pathology. The article presents a brief algorithm for the differential diagnosis of diarrhea in the conditions of the COVID-19 pandemic. KEYWORDS: diarrhea, COVID-19 pandemic, antibiotic-associated diarrhea, ischemic colitis, post-infectious irritable bowel syndrome. FOR CITATION: Gaus O.V., Livzan M.A. Diarrhea syndrome: new accents of patient curation during COVID-19 pandemic. Russian Medical Inquiry. 2021;5(6):446–452 (in Russ.). DOI: 10.32364/2587-6821-2021-5-6-446-452.

scholarly journals Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 303
Author(s):  
Maysaa El Sayed Zaki ◽  
Dina Elhammady ◽  
Mona Foda Salama ◽  
Mostafa Abdelsalam ◽  
Asmaa Osama Bakr Osman
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gastrointestinal Disorder ◽  
The Other ◽  
University Hospital ◽  
Cytolethal Distending Toxin ◽  
Retrospective Case ◽  
Toxin B ◽  
Control Subjects ◽  
Irritable Bowel ◽  
Post Infectious

Background: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, categorized into various subtypes. Post-infection IBS may be attributed to the release of cytolethal distending toxin B (CdtB), which cross-reacts with the adhesion protein vinculin responsible for normal intestinal contractility. Objective: This study aims to identify anti-CdtB and anti-vinculin levels in IBS patients compared to healthy control. Subjects and methods: This retrospective case-control study was conducted on 100 patients with IBS, as determined by a questionnaire based on Rome IV criteria, recruited from the outpatient clinics of the Tropical Medicine at Mansoura University Hospital from January 2019 to January 2020. Results: Anti-vinculin and anti-CdtB levels were significantly elevated in patients with IBS (1.58±0.496ng/ml, 2.47±0.60ng/ml)  when compared to control subjects (1.13±0.249ng/ml, 2.1±0.24 ng/ml), respectively with P=0.001 for both.  Anti-vinculin level was significantly higher in the IBS-D subtype than the other subtypes (P=0.001) while, Anti-CdtB was significantly elevated in IBS-C, IBS-D subgroups compared to control subjects (P=0.001). Conclusion: Findings of the present study support the hypothesis that IBS results from post-infectious disorders initiated by bacterial enteritis. A hypothesis could be applied to all IBS subgroups. On the other hand. These biomarkers might reflect the post-infectious state's severity. These findings need further extensive longitudinal studies in patients with IBS.

scholarly journals Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 303
Author(s):  
Maysaa El Sayed Zaki ◽  
Dina Elhammady ◽  
Mona Foda Salama ◽  
Mostafa Abdelsalam ◽  
Asmaa Osama Bakr Osman
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gastrointestinal Disorder ◽  
The Other ◽  
University Hospital ◽  
Cytolethal Distending Toxin ◽  
Retrospective Case ◽  
Toxin B ◽  
Control Subjects ◽  
Irritable Bowel ◽  
Post Infectious

Background: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, categorized into various subtypes. Post-infection IBS may be attributed to the release of cytolethal distending toxin B (CdtB), which cross-reacts with the adhesion protein vinculin responsible for normal intestinal contractility. Objective: This study aims to identify anti-CdtB and anti-vinculin levels in IBS patients compared to healthy control. Subjects and methods: This retrospective case-control study was conducted on 100 subjects with IBS, as determined by a questionnaire based on Rome IV criteria, recruited from the outpatient clinics of the Tropical Medicine at Mansoura University Hospital from January 2019 to January 2020. Results: Anti-vinculin and anti-CdtB levels were significantly elevated in patients with IBS (1.58±0.496ng/ml, 2.47±0.60ng/ml)  when compared to control subjects (1.13±0.249ng/ml, 2.1±0.24 ng/ml), respectively with P=0.001 for both.  Anti-vinculin level was significantly higher in the IBS-D subtype than the other subtypes (P=0.001) while, Anti-CdtB was significantly elevated in IBS-C, IBS-D subgroups compared to control subjects (P=0.001). Conclusion: Findings of the present study support the hypothesis that IBS results from post-infectious disorders initiated by bacterial enteritis. A hypothesis could be applied to all IBS subgroups. On the other hand. These biomarkers might reflect the post-infectious state's severity. These findings need further extensive longitudinal studies in patients with IBS.

scholarly journals The low-FODMAP diet as an effective tool for managing irritable bowel syndrome – an assessment of adult patients’ knowledge of dietary guidelines

2021 ◽  
pp. 419-426
Keyword(s):  
Irritable Bowel Syndrome ◽  
Support Groups ◽  
Gastrointestinal Symptoms ◽  
Gastrointestinal Disorder ◽  
Elimination Diet ◽  
Dietary Guidelines ◽  
Abdominal Symptoms ◽  
Treatment Objective ◽  
Irritable Bowel ◽  
Fodmap Diet

Background. Irritable bowel syndrome (IBS) is the most common gastrointestinal disorder that is driven by the gutbrain axis and affects 1-20% of the population. Most patients note that various foods elicit abdominal symptoms, and they eliminate these products from their diets. A diet that is low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) is currently one of the mainstays in IBS treatment. Objective. The aim of this study was to assess the knowledge of IBS patients about the disease, treatment and the principles of the low-FODMAP diet that can alleviate gastrointestinal symptoms. Material and methods. The participants were adults diagnosed with IBS, the inclusion criteria were: absence of comorbidities requiring an elimination diet, age over 18 years, and consent to participate in the study. The respondents filled out an anonymous questionnaire containing questions about the IBS diagnosis, disease history and treatment, as well as 45 questions assessing the participants’ knowledge about the low-FODMAP diet. Results. In 28% of the cases, IBS was diagnosed by a general practitioner; in nearly 40% of the cases – by a gastroenterology specialist; in 10% of the cases – by a dietitian, whereas the remaining respondents had arrived at the diagnosis independently or with the help of support groups for IBS patients. After diagnosis, only every fourth respondent sought treatment in a gastroenterology clinic. In the studied population, 237 of the respondents had followed to the low-FODMAP diet, and the differentiating factors were sex (p=0.002), place of residence (city with a population higher than 100,000 vs. rural area; p=0.0001) and education (university vs. vocational school p=0.0043). Respondents who had been recently diagnosed with IBS (less than 12 months vs. more than 12 months before the study) were more likely to follow the FODMAP diet. Conclusions. The surveyed population was characterized by high levels of knowledge about the low-FODMAP diet, but many respondents did not strictly comply with dietary guidelines, in particular the duration of each dietary phase. Age was significantly correlated with the respondents’ knowledge, and the participants’ familiarity with low-FODMAP guidelines decreased with age. Nutritional consultations did not significantly improve the respondents’ knowledge about the low-FODMAP diet.

Post-infectious irritable bowel syndrome: renaissance time?

2021 ◽  
pp. 23-28
Author(s):  
O. V. Gaus ◽  
M. A. Livzan ◽  
D. A. Gavrilenko
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gastrointestinal Symptoms ◽  
Intestinal Infection ◽  
Distinct Phenotype ◽  
Global Spread ◽  
Coronavirus Infection ◽  
Irritable Bowel ◽  
Mechanisms Of Development ◽  
Novel Coronavirus ◽  
Post Infectious

Postinfectious irritable bowel syndrome (PI–IBS) is a distinct phenotype of the disease. The occurrence of gastrointestinal symptoms in PI–IBS is in direct chronological connection with an episode of acute intestinal infection. Previously the problem was considered as the outcome of parasitic, protozoal or bacterial infection. The global spread of a novel coronavirus infection (COVID-19) and increase in the number of new cases of IBS in the population suggests a renaissance of PI–IBS and makes us look at this problem again. This article summarizes and presents modern information on the possible mechanisms of development of PI–IBS, including in persons who have undergone COVID-19.

scholarly journals Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 303
Author(s):  
Maysaa El Sayed Zaki ◽  
Dina Elhammady ◽  
Mona Foda Salama ◽  
Mostafa Abdelsalam ◽  
Asmaa Osama Bakr Osman
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gastrointestinal Disorder ◽  
The Other ◽  
University Hospital ◽  
Cytolethal Distending Toxin ◽  
Retrospective Case ◽  
Toxin B ◽  
Control Subjects ◽  
Irritable Bowel ◽  
Post Infectious

Background: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, categorized into various subtypes. Post-infection IBS may be attributed to the release of cytolethal distending toxin B (CdtB), which cross-reacts with the adhesion protein vinculin responsible for normal intestinal contractility. Objective: This study aims to identify anti-CdtB and anti-vinculin levels in IBS patients compared to healthy control. Subjects and methods: This retrospective case-control study was conducted on 100 subjects with IBS, as determined by a questionnaire based on Rome III criteria, recruited from the outpatient clinics of the Tropical Medicine at Mansoura University Hospital from January 2019 to January 2020. Results: Anti-vinculin and anti-CdtB levels were significantly elevated in patients with IBS (1.58±0.496, 2.47±0.60)  when compared to control subjects (1.13±0.249ng/ml, 2.1±0.24 ng/ml), respectively with P=0.001 for both.  Anti-vinculin level was significantly higher in the IBS-D subtype than the other subtypes (P=0.001) while, Anti-CdtB was significantly elevated in IBS-C, IBS-D subgroups compared to control subjects (P=0.001). Conclusion: Findings of the present study support the hypothesis that IBS results from post-infectious disorders initiated by bacterial enteritis. A hypothesis could be applied to all IBS subgroups. On the other hand. These biomarkers might reflect the post-infectious state's severity.

scholarly journals Alleviation of Irritable Bowel Syndrome-Like Symptoms and Control of Gut and Brain Responses with Oral Administration of Dolichos lablab L. in a Mouse Model

Nutrients ◽  
2018 ◽  
Vol 10 (10) ◽  
pp. 1475 ◽  
Author(s):  
Eunho Chun ◽  
Soojung Yoon ◽  
Amna Parveen ◽  
Mirim Jin
Keyword(s):  
Irritable Bowel Syndrome ◽  
Mouse Model ◽  
Oral Administration ◽  
Visceral Pain ◽  
Gastrointestinal Disorder ◽  
Bowel Habit ◽  
Low Grade ◽  
Dolichos Lablab ◽  
Irritable Bowel ◽  
Post Infectious

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder manifesting as unexplained abdominal pain and bowel habit changes. The pathogenesis of post-infectious IBS is associated with gut–brain axis dysfunction, including low-grade colonic inflammation and anxiety-related long-term brain changes. This study analyzed the efficacy of a standardized extract of Dolichos lablab L. extract (DL), a bean species, in an IBS mouse model resembling post-infectious, diarrhea-dominant IBS. Using a zymosan-induced animal IBS model, we found that oral administration of DL significantly attenuated zymosan-induced increases in colonic macroscopic scores and minimized weight loss without affecting food intake. In the DL-treated mice, the mast cell count and tumor necrosis factor-α level in the colon markedly decreased, similar to results in sulfasalazine-treated mice and in mice with lipopolysaccharide-stimulated bone marrow-derived mast cells. The number of visceral pain-related behaviors was much lower in the DL-treated mice. Anxiety-like behaviors significantly improved, comparable to that after treatment with amitriptyline. The c-Fos expression level in the prefrontal cortex was significantly reduced. Our data suggest that DL could be beneficial for treating IBS by acting on the gut and brain.

scholarly journals Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome

F1000Research ◽  
2021 ◽  
Vol 10 ◽  
pp. 303
Author(s):  
Maysaa El Sayed Zaki ◽  
Dina Elhammady ◽  
Mona Foda Salama ◽  
Mostafa Abdelsalam ◽  
Asmaa Osama Bakr Osman
Keyword(s):  
Irritable Bowel Syndrome ◽  
Gastrointestinal Disorder ◽  
The Other ◽  
University Hospital ◽  
Cytolethal Distending Toxin ◽  
Retrospective Case ◽  
Toxin B ◽  
Control Subjects ◽  
Irritable Bowel ◽  
Post Infectious

Background: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, categorized into various subtypes. Post-infection IBS may be attributed to the release of cytolethal distending toxin B (CdtB), which cross-reacts with the adhesion protein vinculin responsible for normal intestinal contractility. Objective: This study aims to identify anti-CdtB and anti-vinculin levels in IBS patients compared to healthy control. Subjects and methods: This retrospective case-control study was conducted on 100 subjects with IBS, as determined by a questionnaire based on Rome III criteria, recruited from the outpatient clinics of the Tropical Medicine at Mansoura University Hospital from January 2019 to January 2020. Results: The optical density (OD) results of the anti-vinculin and anti-CdtB levels were significantly elevated in patients with IBS (1.58±0.496 OD, 2.47±0.60 OD)  when compared to control subjects (1.13±0.249 OD, 2.1±0.24 OD), respectively with P=0.001 for both.  Anti-vinculin level was significantly higher in the IBS-D subtype than the other subtypes (P=0.001) while, Anti-CdtB was significantly elevated in IBS-C, IBS-D subgroups compared to control subjects (P=0.001). Conclusion: Findings of the present study support the hypothesis that IBS results from post-infectious disorders initiated by bacterial enteritis. A hypothesis could be applied to all IBS subgroups. On the other hand. These biomarkers might reflect the post-infectious state's severity.

scholarly journals Digestive symptoms in daily life of chronic adrenal insufficiency patients are similar to irritable bowel syndrome symptoms

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
L. Quénéhervé ◽  
D. Drui ◽  
J. Blin ◽  
M. Péré ◽  
E. Coron ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Irritable Bowel Syndrome ◽  
Adrenal Insufficiency ◽  
Gastrointestinal Symptoms ◽  
Control Group ◽  
Non Profit ◽  
Acute Adrenal Insufficiency ◽  
Irritable Bowel ◽  
Rome Iv

AbstractGastrointestinal symptoms are frequent in acute adrenal insufficiency. Although digestive symptoms can significantly reduce quality of life, they are rarely described in patients with treated chronic adrenal insufficiency (CAI). We aimed to characterize digestive symptoms in CAI patients. We used the section pertaining functional bowel disorders of the Rome IV questionnaire. A questionnaire was published on the website of the non-profit patient association “Adrenals” (NPPA of CAI patients) for five months. Information on demographics, characteristics of adrenal insufficiency, digestive symptoms and quality of life was collected. The relatives of CAI patients served as a control group. We analyzed responses of 33 control subjects and 119 patients (68 primary adrenal insufficiency (PAI), 30 secondary adrenal insufficiency (SAI) and 21 congenital adrenal hyperplasia (CAH)). Abdominal pain at least once a week over the past 3 months was reported by 40%, 47% and 33% of patients with PAI, SAI and CAH respectively versus 15% for the controls (p = 0.01). Symptoms were consistent with the Rome IV criteria for irritable bowel syndrome in 27%, 33% and 33% of patients respectively versus 6% for the controls (p < 0.0001). Quality of life was described as poor or very poor in 35%, 57% and 24% of patients respectively versus 5% for the controls (p < 0.0001). In conclusion, digestive symptoms are frequent and incapacitating in CAI patients and similar to symptoms of irritable bowel syndrome in 30% of CAI patients. Assessment and management of digestive symptoms should be considered a priority for physicians treating patients with CAI.

scholarly journals The Prevalence of Anti-Zein Antibodies: A Comparative Study between Celiac Disease and Irritable Bowel Syndrome

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 649
Author(s):  
Luis Alberto Sánchez-Vargas ◽  
Karina Guadalupe Hernández-Flores ◽  
Francisco Javier Cabrera-Jorge ◽  
José María Remes-Troche ◽  
Job Reyes-Huerta ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Celiac Disease ◽  
Gastrointestinal Disorder ◽  
Newly Diagnosed ◽  
Disease Group ◽  
Immune Mediated ◽  
Healthy Control ◽  
Gliadin Peptides ◽  
Irritable Bowel ◽  
First Time

Celiac disease (CD) is a chronic immune-mediated enteropathy triggered by exposure to dietary gluten in genetically predisposed individuals. In contrast, irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder affecting the large intestine, without an autoimmune component. Here, we evaluated the prevalence of IgA and IgG antibodies to maize zeins (AZA) in patients with CD and IBS. Using an in-house ELISA assay, the IgA and IgG anti-zein antibodies in the serum of 37 newly diagnosed CD (16 biopsy proved and 21 serological diagnosis) and 375 IBS patients or 302 healthy control (HC) subjects were measured. Elevated levels of IgA AZA were found in CD patients compared with IBS patients (p < 0.01) and HC (p < 0.05). CD patients had the highest prevalence (35.1%), followed by IBS (4.3%) and HCs (2.3%) (p < 0.0001). IgG AZA antibodies were not found in any CD patients, IBS patients, or HC subjects. A significant positive correlation was found between IgA AZA with IgA anti-gliadin (AGA, r = 0.34, p < 0.01) and IgA anti-deaminated gliadin peptides (DGP, r = 0.42, p < 0.001) in the celiac disease group. Taken together, our results show for the first time a higher prevalence of AZA IgA antibodies in newly diagnosed CD patients than in IBS patients, confirming a biased immune response to other gliadin-related prolamins such as maize zeins in genetically susceptible individuals.

Sign in / Sign up

Export Citation Format

Share Document